SPAC Overview
Timeline Progress
About
Altamont Pharma Acquisition Corp. is a blank-check company formed to pursue an initial business combination. It intends to target companies domiciled in North America or Europe developing assets in biopharma and medical technology, with a broader stated focus on healthcare innovation.
Investment Focus
Healthcare, Biopharmaceuticals
Geographic Focus
North America, Europe
The terms and the filing trail behind Altamont Pharma Acquisition Corp.
What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.
- Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
- Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
- The full 8-K lifecycle timeline, each event linked to its filing
- Price history across the unit, share and warrant tickers
- Follow it, and see it change on your watchlist
SPAC Team
Sponsors
Leadership
Underwriters
Extended Team Information
The team is led by Mark Pearson, founder and CEO of Altamont Pharma, and is advised by John D. Harkey, Jr. of JDH and Jay Shepard. Their backgrounds include healthcare investing, biotech and pharmaceutical company leadership, drug development, and successful healthcare transactions.